C5AR1 and COVID-19: To keep combating the inflammation, eculizumab is at the moment the only medication approved for humans to prevent the complement cascade in order to ameliorate the pulmonary dysfunction due to COVID-19, but also specific C5aR1 blockade is a very promising therapy to fight against severe COVID-19.